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Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic
Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting
Downstream Pro-Fibrotic Signaling
Steven T. Haller, PhD; Yanling Yan, PhD; Christopher A. Drummond, PhD; Joe Xie, MD; Jiang Tian, PhD; David J. Kennedy, PhD;
Victoria Y. Shilova, PhD; Zijian Xie, PhD; Jiang Liu, PhD; Christopher J. Cooper, MD; Deepak Malhotra, MD, PhD; Joseph I. Shapiro, MD;
Olga V. Fedorova, PhD; Alexei Y. Bagrov, MD, PhD
Background-—Experimental uremic cardiomyopathy causes cardiac fibrosis and is causally related to the increased circulating
levels of the cardiotonic steroid, marinobufagenin (MBG), which signals through Na/K-ATPase. Rapamycin is an inhibitor of the
serine/threonine kinase mammalian target of rapamycin (mTOR) implicated in the progression of many different forms of renal
disease. Given that Na/K-ATPase signaling is known to stimulate the mTOR system, we speculated that the ameliorative effects of
rapamycin might influence this pathway.
Methods and Results-—Biosynthesis of MBG by cultured human JEG-3 cells is initiated by CYP27A1, which is also a target for
rapamycin. It was demonstrated that 1 lmol/L of rapamycin inhibited production of MBG in human JEG-2 cells. Male Sprague-
Dawley rats were subjected to either partial nephrectomy (PNx), infusion of MBG, and/or infusion of rapamycin through osmotic
minipumps. PNx animals showed marked increase in plasma MBG levels (102560 vs 37753 pmol/L; P<0.01), systolic blood
pressure (1691 vs 1111 mm Hg; P<0.01), and cardiac fibrosis compared to controls. Plasma MBG levels were significantly
decreased in PNx-rapamycin animals compared to PNx (37346 vs 102560 pmol/L; P<0.01), and cardiac fibrosis was
substantially attenuated by rapamycin treatment.
Conclusions-—Rapamycin treatment in combination with MBG infusion significantly attenuated cardiac fibrosis. Our results
suggest that rapamycin may have a dual effect on cardiac fibrosis through (1) mTOR inhibition and (2) inhibiting MBG-mediated
profibrotic signaling and provide support for beneficial effect of a novel therapy for uremic cardiomyopathy. ( J Am Heart Assoc.
2016;5:e004106 doi: 10.1161/JAHA.116.004106)
Key Words: cardiac fibrosis • cardiomyopathy • cardiovascular diseases • fibrosis • heart failure
T he high mortality rate in patients with chronic renalfailure is ultimately attributed to severe cardiovascular
disease.1 This uremic cardiomyopathy is characterized by
cardiac hypertrophy, diastolic dysfunction, and cardiac fibro-
sis along with elevated circulating concentrations of the
cardiotonic steroid marinobufagenin (MBG), a ligand of Na/
K-ATPase. MBG belongs to a family of bufadienolides previ-
ously described in amphibians.2 We have shown that MBG is
elevated in patients with renal failure3 and in rats subjected to
partial nephrectomy (PNx), and those with pharmacological
administration of MBG developed a similar cardiomyopathy as
observed in patients, whereas active immunization against
MBG attenuated this in PNx.4,5 In PNx rats, we also observed
increased cardiac and plasma levels of carbonylated proteins
as well as evidence for signaling through Na/K-ATPase, such
as activation of Src and mitogen-activated protein kinase.4,5 A
recent report from our group has shown that treatment with a
monoclonal antibody directed against MBG drastically
reduced cardiac fibrosis in PNx animals.6
The mammalian target of rapamycin (mTOR) is a serine/
threonine kinase composed of 2 signaling complexes,
mTORC1 and mTORC2.7 The mTORC1 complex is involved
in cellular proliferation and growth, whereas mTORC2 is
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involved in the regulation of the cytoskeleton.8 The mTOR
pathway has been implicated in the progression of many
different forms of renal disease, including experimentally
induced uremic cardiomyopathy and development of renal
fibrosis.9–11 MBG has been shown to activate the mTOR
pathway in cardiac myocytes.12 Treatment with rapamycin
(an mTORC1 inhibitor) has been shown to attenuate inflam-
mation, fibrosis, and cardiac hypertrophy in experimental
models of renal disease.9,10 Rapamycin is also a competitive
inhibitor of cytochrome P450, family 27, subfamily a,
polypeptide 1 (CYP27A1), a key rate-limiting enzyme of the
bile acid pathway.13 A recent report by Fedorova et al
provides compelling evidence that the alternative bile acid
pathway, initiated by CYP27A1 from cholesterol, is responsi-
ble for the production of MBG in mammals, specifically in rat
adrenocortical cells and tissue and in human placental
chorionic epithelial cells (JEG-3).14
Based on this background, the primary goals of the present
study were to (1) examine the effects of rapamycin on
MBG production in vitro on a cell line known to synthesize
MBG (ie, JEG-3 placental cells15) and (2) determine the effects
of rapamycin on cardiac fibrosis and MBG production in vivo
using the rat PNx model of uremic cardiomyopathy. In
addition, given that we have shown that MBG induces
increases in cardiac procollagen-1 and reactive oxygen
species (ROS),4,5 we sought to determine the effect of
rapamycin on procollagen-1 and ROS production in cardiac
fibroblasts.
Methods
Animal Studies
All animal experimentation described in this article was
conducted in accord with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals under
protocols approved by the University of Toledo Institutional
Animal Care and Use Committee. Male Sprague-Dawley rats
(250–300 g) were used for these studies. Rats were divided
into 6 groups. In the first group, PNx (n=10) was performed as
we have previously described.5 In the second group, PNx was
performed and rapamycin (Rapa) was administered (0.2 mg/
kg per day; n=6).16 The third group received both rapamycin
(0.2 mg/kg per day) and MBG (10 lg/kg per day; n=8). The
fourth and fifth groups were administered MBG alone (10 lg/
kg per day; n=8) and rapamycin alone (0.2 mg/kg per day;
n=8). The dose of MBG is the same as we have previously
reported.4,5 The sixth group consisted of sham operated
controls (n=8). All treatments were performed for 4 weeks
with the use of osmotic minipumps (model 2004, ALZET;
DURECT Corporation Cupertino, CA). Minipumps were
inserted subcutaneously through a flank incision. Two
minipumps were implanted for coadministration of rapamycin
and MBG.
Blood Pressure, Cardiac Physiology, and Other In
Vivo Measurements
Blood pressure (BP) was determined using the tail-cuff
method by IITC (Amplifier model 229, Monitor model 31,
Test chamber Model 306; IITC Life Science, Woodland Hills,
CA) at baseline, and once-weekly for 4 weeks. Then, rats were
euthanized and the heart weight and cardiac histology were
determined. Plasma samples were stored at 80°C for
biochemical analysis. Plasma MBG and creatinine were
measured as we have previously described.6,17
Isolation of Cardiac Fibroblasts and JEG-3 Cell
Experiments
Isolation of cardiac fibroblasts was carried out as previously
reported by Brilla et al, with modifications.4,18–20 Cardiac
fibroblasts were grown to confluence in DMEM with 15% FBS
and starved for 18 to 24 hours in medium containing 1% FBS
before treatment. Cells were treated with rapamycin at a
concentration of 0.1 and 0.01 lmol/L for 24 hours in media
containing 1% FBS.21 Cells were also treated with either MBG
alone at concentrations shown to induce procollagen produc-
tion (1 and 100 nmol/L)19 or in combination with rapamycin.
Cell lysates were prepared by washing the cells twice with ice-
cold PBS and incubating them on ice for 20 minutes with lysis
buffer containing 10 mmol/L of Tris-HCL (pH 7.5), 0.5%
Nonidet P-40, and protease and phosphatase inhibitors. Cell
lysates were collected, vortexed for 30 seconds, and used
immediately or stored at 80°C. Although we did not directly
address the effects of cell proliferation on cardiac fibroblasts,
in our experiments the cardiac fibroblasts were grown to
confluence before serum starvation and treatment, and we did
not visually note any significant morphological differences
between rapamycin-treated and untreated cells that might
indicate any effects on proliferation. Furthermore, Poulalhon
et al performed similar experiments in lung fibroblasts and did
not note changes in proliferation at similar concentrations
used.21
Human placental chorionic epithelial cells (JEG-3) were
purchased from a commercially available vendor (ATCC,
Manassas, VA), cultured in 6-well plates, and grown to
confluence 80% to 85% in Eagle’s minimum essential media
(ATCC). Then, the 10% FBS media was replaced by 2.5% FBS
media and rapamycin (1 lmol/L) was added into half the
wells. Both vehicle-treated control cells and rapamycin-
treated cells were sampled after 3 and 6 hours of incubation.
Cultured media was collected for MBG measurements, and
cells were collected for total protein measurement.14 MBG
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was extracted from the collected media using C18 columns
(Waters, Milford, MA) as previously reported.17 Competitive
immunoassays were performed using a monoclonal anti-MBG
antibody to determine the concentration of MBG in the
samples also as previously reported.17
Protein Carbonylation
Whole-cell lysates were prepared as aforementioned. Fifteen
microgram of proteins from each sample were denatured with
6% SDS (final concentration), derivatized with 19 DNPH, and
neutralizedwith neutralization buffer (30% of glycerol in 2 mol/L
of Tris). Protein carbonylation levels were monitored by western
blot with anti-DNP antibody (Sigma D9656; Sigma-Aldrich, St.
Louis, MO). Ponceau S (Sigma P7170; Sigma-Aldrich) staining of
the membrane was used to verify uniform loading before
immunoblotting with indicated antibodies.
Western Blot Analysis
Western blot analysis was performed on proteins from tissue
homogenates and cell lysates as previously reported.4,6,18,19
Goat anti-type 1 collagen antibody (Southern Biotech, Birm-
ingham, AL) was used to probe for collagen-1, and secondary
anti-goat antibody was purchased from Santa Cruz Biotech-
nology (Dallas, TX). Rabbit anti-phospho-S6 antibody and total
S-6 antibody were purchased from Cell Signaling Technology
(Danvers, MA). For detection, we used ECL and ECL plus
purchased from Amersham Biosciences (Foster City, CA).
Loading conditions were controlled using anti-actin goat
polyclonal antibody (Santa Cruz Biotechnology).
Histology
Left ventricle sections were immediately fixed in 4% formalin
buffer solution (pH 7.2) for 18 hours, dehydrated in 70%
ethanol, and then embedded in paraffin and cut with a
microtome. Fast green staining with Sirius red (0.1%) was
performed on left ventricular tissues as described previously.22
For quantitative morphometric analysis, 10 random images of
Sirius red/Fast green stained slides were taken at 920
magnification and electronically scanned into an RGB image
which was analyzed using ImageJ software (ImageJ 1.36b; NIH,
Bethesda, MD). The amount of fibrosis was then estimated with
a macro by converting pixels of the image with substantially
greater (>120%) red than green intensity to have the new
grayscale amplitude=1, leaving other pixels as with ampli-
tude=0. Representative photomicrographs were selected from
the 10 random images taken from each group based on the
quantified analysis. For confirmation of the histological find-
ings, quantitative determination of collagen-1 in left ventricular
homogenates was performed using western blot.
Statistical Analysis
The results are presented as meansSEM. Data were
analyzed using one-way ANOVA and repeated-measures
ANOVA. If there was significant group difference shown by
ANOVA, then post-hoc confidence intervals for pair-wise
differences were conducted using the Tukey-Kramer proce-
dure to control for the family-wise error rate when making all
pair-wise difference in mean comparisons. Other multiple
comparisons were constructed based on the simultaneous
inference procedures proposed by Hothorn et al.23 All
analyses were performed in SAS (version 9.4; SAS Institute
Inc., Cary, NC), R (version 3.0.; R Foundation for Statistical
Computing, Vienna, Austria), and GraphPad Prism software
(GraphPad Software Inc., San Diego, CA). A 2-sided P value of
less than 0.05 was considered to be statistically significant.
Results
Effect of Rapamycin on MBG Production by JEG-3
Cells
The chemical structure of MBG is shown in Figure 1A.
Cultured human placental JEG-3 cells were treated with
1 lmol/L of rapamycin to test the effects on MBG produc-
tion. As presented in Figure 1B, rapamycin treatment signif-
icantly reduced MBG production compared to vehicle treated
controls after 3 and 6 hours of treatment (84 vs 60 pmol/g of
protein; P<0.01; and 243 vs 116 pmol/g of protein; P<0.01,
correspondingly).
Effect of Rapamycin on BP, MBG Levels
Rapamycin treatment alone demonstrated a slight elevation in
systolic BP (1233 vs 1111 mm Hg; P=NS [not significant]),
but did not significantly alter MBG levels compared to control
animals (Table). PNx surgery substantially increased the heart
weight/body weight ratio. PNx surgery and MBG infusion
produced sustained hypertension throughout the duration of
the experiment. PNx plasma MBG levels were similar to the
MBG levels produced by MBG infusion alone (102560 vs
109257 pmol/L; P=NS). PNx surgery with rapamycin infu-
sion showed a significant decrease in systolic BP by the third
week (1492 vs 1661 mm Hg; P<0.01) compared to PNx
alone, which persisted at 4 weeks when analyzed by t test
(P<0.05), yet not by pair-wise comparison. PNx surgery with
rapamycin treatment also demonstrated a drastic decrease in
MBG levels compared to PNx alone (37346 vs
102560 pmol/L; P<0.01), although rapamycin treatment
did not affect plasma MBG levels in normal animals. Coadmin-
istration of MBG with rapamycin did not attenuate systolic BP
or plasma MBG levels. These data are summarized in Table.
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Effect of Rapamycin on Cardiac Fibrosis
Cardiac fibrosis was assessed in the left ventricular myocardium
by histological analysis (Sirius red with Fast green staining) and
collagen1 expression determined bywestern blot. Both PNx and
MBG infusion resulted in substantial increases in collagen
expression and cardiac scarring, whereas PNx with rapamycin
infusion and coadministration of rapamycin with MBG signifi-
cantly attenuated these effects (Figure 2A and 2B).
Effect of MBG and Rapamycin on Cardiac
Fibroblast Phosphoribosomal S6, and
Procollagen-1 Protein Expression
Activation of the mTOR pathway results in phosphorylation
of ribosomal S6, which is commonly used as an indicator
of mTOR activation.9,10,12 Cultured cardiac fibroblasts
treated with 1 and 100 nmol/L of MBG resulted in a
significant increase in phosphorylation of ribosomal S6
Figure 1. A, Chemical structure of marinobufagenin (MBG), 3b,5b-dihydroxy-14,15-epoxy bufadienolide,
PubChem CID: 11969465. B, MBG production in human placental chorionic epithelial cells (JEG-3 cells)
after incubation with 1 lmol/L of rapamycin (Rapa) for 3 and 6 hours. *P<0.05 versus control; **P<0.01
versus control.
Table. Effects of Rapamycin (Rapa) on Physiological Measurements After PNx or Infusion of MBG
Group Sham (n=8) Rapa (n=8) PNx (n=10) PNx+Rapa (n=6) MBG (n=8) MBG+Rapa (n=8)
Systolic BP, mm Hg
Baseline 1101 1131 1131 1121 1131 1131
Week 1 1042 1111 1311* 1301 1211* 1131‡
Week 2 1041 1201 1341* 1351 1221* 1281‡
Week 3 1052 1132 1661* 1492† 1361* 1232‡
Week 4 1111 1233 1691* 1516† 1391* 1452
Heart weight
BW, g 5290.01 5330.02 4250.02* 3680.04 4930.01 5280.01
HW, g 1.370.02 1.470.07 1.490.06 1.230.10† 1.320.05 1.380.04
HW/BW, 9103 2.600.06 2.770.08 3.570.20* 3.420.24 2.730.08 2.630.05
Plasma measurements
Creatinine, mg/dL 0.390.06 0.480.03 0.550.04 0.570.09 0.310.03 0.510.11
MBG, pmol/L 37753 43942 102560* 37346† 109257* 109390
Data are presented as meanSEM. For clarity purposes, statistical significance is designated for the following groups: sham versus PNx, sham versus MBG, PNx versus PNx+Rapa, and
MBG versus MBG+Rapa. For complete pair-wise differences, please refer to Figures S1 through S10. Sham refers to animals subject to sham surgery; PNx refers to partial nephrectomy;
PNx+Rapa refers to PNx surgery and rapamycin infusion using minipumps; Rapa refers to rapamycin infusion using minipumps; MBG+Rapa refers to coadministration of MBG and
rapamycin using minipumps; and MBG refers to MBG infusion using minipumps. BP indicates blood pressure; BW, body weight; HW, heart weight; MBG, marinobufagenin.
*P<0.01 versus sham.
†
P<0.01 versus PNx.
‡
P<0.01 versus MBG.
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protein expression determined by western blot compared
to controls, indicating activation of the mTOR pathway
(P<0.01; Figure 3). Treatment with rapamycin at
0.1 lmol/L alone and in combination with MBG at 1
and 100 nmol/L caused a significant reduction in phos-
pho-S6 expression compared to MBG treatment (P<0.01;
Figure 3). Treatment with low-dose rapamycin
(0.01 lmol/L) in combination with MBG resulted in a
less-profound reduction in phospho-S6 expression (Fig-
ure 3; P=NS). MBG treatment at 1 and 100 nmol/L
resulted in a significant increase in procollagen-1 protein
expression compared to controls (both P<0.01; only
100 nmol/L data shown in Figure 4). Both the high-
(0.1 lmol/L) and low-dose (0.01 lmol/L) rapamycin
treatments significantly attenuated MBG-induced procolla-
gen-1 expression (P<0.01; Figure 4).
Effect of MBG and Rapamycin on Cardiac
Fibroblast Oxidative Stress
MBG treatment (100 and 1 nmol/L) resulted in a significant
increase in oxidative stress asmeasured by carbonylated protein
expression compared to controls (P<0.01; Figure 5). Treatment
with high-dose rapamycin in combination with MBG at both 100
and 1 nmol/L significantly attenuated these effects (Figure 5).
Treatment with low-dose rapamycin significantly reduced oxida-
tive stress in combinationwithMBGat 100 nmol/L compared to
MBG 100 nmol/L alone (P<0.01, data not shown).
Discussion
The mTOR pathway has been shown to play a pivotal role in
several different forms of renal disease.9 Treatment with
Figure 2. A, Representative (top) and quantitative analysis of collagen 1 (meanSEM) western blots performed on cardiac tissue from the
different groups. Actin was used as a loading control. B, Representative Sirius red and Fast green stained photomicrographs obtained from
cardiac tissue derived from the different experimental groups. Scale bar=100 lmol/L. Amount of fibrosis expressed as meanSEM measured
using computer-assisted morphometry, as we have previously described.5 Sham refers to animals subject to sham surgery (n=8); PNx refers to
partial nephrectomy (n=10); PNx+Rapa refers to PNx surgery and rapamycin infusion using minipumps (n=6); Rapa refers to rapamycin infusion
using minipumps (n=8); MBG+Rapa refers to coadministration of marinobufagenin (MBG) and rapamycin using minipumps (n=8); and MBG refers
to MBG infusion using minipumps (n=8). *P<0.01 versus sham and Rapa; **P<0.01 versus PNx and MBG; #P<0.05 versus sham.
DOI: 10.1161/JAHA.116.004106 Journal of the American Heart Association 5
Rapamycin Attenuates Cardiac Fibrosis Haller et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 18, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
rapamycin attenuates many of the physiological changes
associated with a decrease in renal function, including
interstitial fibrosis.9 Our current work demonstrates that
rapamycin treatment, in the setting of experimental uremic
cardiomyopathy, significantly reduces cardiac fibrosis. This is
in support of a recent report with similar findings in a murine
model of uremic cardiomyopathy.10 In the previously men-
tioned report, Siedlecki et al used a PNx mouse model to
demonstrate that administration of rapamycin (2 mg/kg per
day for 4 weeks) 4 weeks post-PNx was able to reverse
cardiac hypertrophy and fibrosis.10 Importantly, MBG was not
measured in their study.10 In the current study, we demon-
strated similar reductions in cardiac hypertrophy and fibrosis
by administration of rapamycin concurrent with the PNx
procedure. Furthermore, we demonstrate that rapamycin
attenuates MBG production both in vitro (Figure 1B) and
in vivo (Table) and that rapamycin is capable of attenuating
MBG induced increases in both collagen formation (Figure 4)
and protein carbonylation (Figure 5) in cardiac fibroblasts.
Recent work in animal models of renal disease has
provided compelling evidence for the involvement of mTORC1
in the generation of fibrosis. In an animal model of unilateral
obstructive nephropathy, as well as in fibroblasts, the
profibrotic cytokine transforming growth factor beta (TGF-b)
was shown to activate mTORC1 acting through a phospho-
inositide 3-kinase pathway.24 In human fibroblasts, the mTOR
pathway has been shown to regulate collagen type I
production.25 Treatment with rapamycin has been shown to
decrease TGF-b, fibroblast proliferation, and renal fibro-
sis.24,26,27 In support of our results, rapamycin treatment
significantly decreased cardiac fibrosis, as evaluated by
trichrome staining, in a murine model of uremic cadiomyopa-
thy.10 Similar results were reported using a transverse aortic
constriction model.28
We have shown that MBG causes many of the pathophys-
iological changes associated with experimental uremic car-
diomyopathy, including cardiac fibrosis,5 and that MBG
induces cardiac fibroblasts to produce collagen.4 The tran-
scription factor, Friend leukemia integration-1 (Fli-1), acts as a
negative regulator of collagen production,29,30 and activation
of protein kinase C-delta (PKC-d) can phosphorylate Fli-1 to
promote collagen synthesis.31 We have recently reported that
Figure 3. Representative (top) and quantitative analysis of phos-
phoribosomal S6 protein western blots derived from cardiac
fibroblasts treated with marinobufagenin (MBG; 1 or 100 nmol/
L), rapamycin (Rapa; 0.01 or 0.1 lmol/L), or in combination with
the corresponding quantitative data shown as the meanSEM of 5
experiments. Total ribosomal S6 protein was used as loading
control. *P<0.01 versus control; **P<0.01 versus MBG 100 nmol/
L, MBG 100 nmol/L+Rapa 0.01 lmol/L, MBG 1 nmol/L, and MBG
1 nmol/L+Rapa 0.01 lmol/L.
Figure 4. Representative (top) and quantitative analysis of pro-
collagen-1 western blots derived from cardiac fibroblasts treated
with marinobufagenin (MBG) 100 nmol/L with or without rapamy-
cin (Rapa; 0.01 or 0.1 lmol/L) with the corresponding quantitative
data shown as the meanSEM of 5 experiments. *P<0.01
versus control; #P<0.05 versus control; **P<0.01 versus MBG
100 nmol/L.
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MBG induces translocation of PKC-d, which phosphorylates
Fli-1 and leads to an increase in collagen synthesis.18
Signaling through PKC-d has been shown to activate the
mTOR pathway.32
Progression of uremic cardiomyopathy begins with con-
centric hypertrophy, which results in decreases in ventricular
systolic dimension and increased ejection fraction in the
heart. It is known that this concentric hypertrophy cannot
persist permanently because hypertrophy of individual
myocytes occurs to such an extent that they then do not
oxygenate well and cell death occurs, leading to pathological
hypertrophy consisting of ventricular dilation and decreased
ejection fraction.33 Interestingly, even mild degrees of chronic
renal failure appear to confer a significant increase in cardiac
disease.34 Using the currently proposed model of PNx in both
mice and rats, we have shown that the concentric phase of
hypertrophy occurs within 4 weeks,5,35,36 whereas patholog-
ical hypertrophy occurs within 8 weeks after the PNx
procedure.35,37 The current study concluded at 4 weeks,
and although blood urea nitrogen measurements were not
performed, we did measure cystatin C in the sham versus PNx
rats, and this indicated levels that also increased significantly
(106570 vs 2668215 ng/mL; P<0.01).
The data summarized in Table indicate that rapamycin is
capable of antagonizing the cardiac hypertrophy observed in
PNx, and that this effect does not appear to be mediated by
indirect effects on blood pressure. This is consistent with our
observations that increased synthesis of cardiotonic steroids,
such as MBG, plays a central role in mediating the cardiac
growth effects observed in the PNx model,5,6 and that these
effects are independent of changes in BP given that antihy-
pertensive therapy does not reduce cardiac hypertrophy and
fibrosis post-PNx.35 In the current study, we demonstrate that
rapamycin antagonizes the synthesis of MBG both in vitro
(JEG-3 cells; Figure 1B) as well as in the in vivo PNx model.
Given that rapamycin was not effective in antagonizing the
cardiac growth effects or MBG levels observed with exoge-
nous administration of MBG in vivo (Table), this underscores
the notion that rapamycin mainly exerts its effects through
blocking endogenous MBG production in this model. We did
not observe any notable side effects in rats administered
MBG. The dose of MBG used (10 lg/kg per day by
subcutaneous minipump) did produce a modest decrease in
body weight, although the heart weight/body weight ratio was
also modestly, but not significantly, increased in the MBG
group versus sham. Based on our in vitro data, we demon-
strated that MBG is capable of inducing collagen formation in
cardiac fibroblasts; thus, we expect that the increased fibrosis
noted in MBG-treated animals was the result of this increased
collagen formation in vivo.
Treatment with rapamycin significantly reduced circulating
MBG levels compared to PNx animals. In addition, treatment
with rapamycin in JEG-3 cells, which produce MBG, resulted in
a 52% reduction in MBG levels after 6 hours of treatment.
Cardiotonic steroid production is not sex specific, and we
have previously shown that whereas partial nephrectomy
caused the induction of smaller increases in blood pressure of
female rats, both male and female rats are similarly suscep-
tible to cardiac remodeling, hypertrophy, and fibrosis in this
model, where cardiotonic steroids are elevated in both
Figure 5. Representative and quantitative analysis of carbonylated protein western blots derived from
cardiac fibroblasts treated with marinobufagenin (MBG; 100 or 1 nmol/L), rapamycin (Rapa; 0.1 lmol/L)
or in combination with the corresponding quantitative data shown as the meanSEM of 5 experiments.
Ponceau S staining of the membrane was used to control for loading. A; *P=0.01 versus control; **P<0.01
versus control; ##P=0.01 versus MBG 100 nmol/L; #P<0.05 versus MBG 1-nmol/L treatment.
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sexes.36 In addition to the adrenal cortex,4,14,38 the placenta
is a known source of MBG synthesis, and our group and
others have demonstrated the involvement of cardiotonic
steroids, such as MBG, in the pathogenesis of preeclamp-
sia.15,17,39–41 It was demonstrated that elevated plasma MBG
levels in preeclampsia are responsible for BP increase and for
the fibrosis development in placenta and umbilical arteries of
preeclamptic patients versus controls with normal pregnan-
cies, and immunoneutralization of MBG ex vivo results in
improvement of vasorelaxation and reduces fibrosis and
stiffening of umbilical arteries.2,15,17,41–45 Accordingly, the
JEG-3 cell line has been commonly used to study production
of cardiotonic steroids such as MBG in vitro, thus these
experiments were performed as a proof of concept that
rapamycin is capable of interrupting synthesis of cardiotonic
steroids such as MBG.
Endogenous cardiotonic steroids have been postulated to
be synthesized from the classic steroidogenesis pathway
through cholesterol side-chain cleavage and pregnenolone
precursors.2 Though this theory is still upheld for other
cardiotonic steroids, such as ouabain, there have been
controversial results with regard to MBG production.2 In toads,
the biosynthesis of MBG occurs through the bile acid pathway
form cholanic acids.46 Rapamycin acts as a competitive
inhibitor of CYP27A1, a key rate-limiting enzyme of the bile
acid pathway. Our data provide preliminary evidence indicating
that the drastic reduction in MBG levels in both PNx animals
and JEG-3 cells, treated with rapamycin, may be attributed to
competitive inhibition of CYP27A1. Our results are supported
by the work of Fedorova et al, which demonstrated that post-
transcriptional silencing of CYP27A1 in human JEG-3 cells and
rat adrenocortical cells significantly reduced bile acid produc-
tion and MBG.14 In addition, the investigators report that Dahl-
S rats, following a high-salt diet, demonstrated that a
significant elevation in circulating MBG levels was accompa-
nied by upregulation of adrenocortical CYP27A1 mRNA and
increase in CYP27A1 protein levels.14 Thus, in the setting of
experimental uremic cardiomyopathy, rapamycin may have a
dual effect of both inhibiting cardiac fibrosis and reducing MBG
production. Interestingly, rapamycin did not reverse the
hypertensive response in rats treated with MBG (Table) in the
presence of a pronounced effect on collagen abundance
(Figure 2). MBG initiates ionic and signaling pathways by
binding to Na/K-ATPase.2 The former pathway participates in
BP regulation through increased contractility of vascular
smooth muscle cells, and the latter pathway initiates profi-
brotic signaling. Thus, rapamycin may block the profibrotic
effect of MBG downstream in the setting of exogenous MBG in
the circulation without affecting ionic signaling.2
Importantly, we did see a significant reduction in cardiac
fibrosis with combined MBG infusion and rapamycin treat-
ment, although we did not observe substantial effects on
plasma MBG levels with coadministration of rapamycin. In the
current study, we demonstrated that MBG-induced oxidative
stress is significantly attenuated by treatment with rapamycin
in cardiac fibroblasts (Figure 5). Although the bulk of our
in vitro work would suggest that rapamycin causes both
reductions in MBG synthesis as well as interferes with the
cardiotonic steroid signaling process at a postreceptor level
(ie, distal to the Na/K-ATPase), it is still unclear where this
interference occurs, and whether higher doses of rapamycin
would overcome the effects of continuous MBG infusion.
In conclusion, the mTOR pathway has been implicated in
the generation of renal fibrosis during renal failure. Our results
suggest that treatment with rapamycin has a dual effect of
both blocking the mTOR pathway and reducing MBG levels
resulting in attenuation of cardiac fibrosis. Treatment with
rapamycin may provide a novel therapy for reducing
MBG levels and cardiac fibrosis in the setting of uremic
cardiomyopathy.
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Supplemental Figure Legend: 
Figure S1:  Pairwise comparisons of baseline systolic blood pressure with a 95% family-
wise confidence level. 
Figure S2:  Pairwise comparisons of week one systolic blood pressure with a 95% 
family-wise confidence level. Red lines indicate statistical significance at p<0.01. 
Figure S3:  Pairwise comparisons of week two systolic blood pressure with a 95% 
family-wise confidence level. Red lines indicate statistical significance at p<0.01. 
Figure S4:  Pairwise comparisons of week three systolic blood pressure with a 95% 
family-wise confidence level. Red lines indicate statistical significance at p<0.01. 
Figure S5:  Pairwise comparisons of week four systolic blood pressure with a 95% 
family-wise confidence level. Red lines indicate statistical significance at p<0.01. 
Figure S6:  Pairwise comparisons of body weight with a 95% family-wise confidence 
level. Red lines indicate statistical significance at p<0.01. 
Figure S7:  Pairwise comparisons of heart weight with a 95% family-wise confidence 
level. Red lines indicate statistical significance at p<0.01. 
Figure S8:  Pairwise comparisons of heart weight/body weight ratio with a 95% family-
wise confidence level. Red lines indicate statistical significance at p<0.01. 
Figure S9:  Pairwise comparisons of creatinine with a 95% family-wise confidence level. 
Red lines indicate statistical significance at p<0.01. 
Figure S10:  Pairwise comparisons of Marinobufagenin (MBG) with a 95% family-wise 
confidence level. Red lines indicate statistical significance at p<0.01. 
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